MDWD MediWound Ltd.
Price Chart
Executive Summary
MediWound reported a decline in Q4 and full-year 2025 revenue, driven by lower development services due to the U.S. government shutdown and reduced product sales to Vericel. Despite higher R&D spending on the EscharEx Phase III trial, the company maintained a strong cash position of $53.6 million and reaffirmed its 2026–2028 revenue guidance. The stock remains speculative, tied to upcoming clinical and regulatory catalysts.
Key Financial Metrics
Actionable Insight
Traders should monitor progress of the EscharEx Phase III trial and regulatory approvals for the new NexoBrid facility as key near-term catalysts. While cash is strong, continued revenue declines and negative EBITDA suggest ongoing execution risk. The reaffirmed guidance provides some forward hope, but near-term fundamentals are weak.
Key Facts
- Q4 2025 revenue was $1.9 million, down 67% from $5.8 million in Q4 2024
- Full-year 2025 revenue was $17.0 million, down from $20.2 million in 2024
- Net loss for 2025 was $23.9 million, or $2.10 per share, compared to $30.2 million, or $3.03 per share, in 2024
- Cash balance increased to $53.6 million at year-end, up from $43.6 million, due to a $30 million registered direct offering
- Company reaffirmed 2026 revenue guidance of $24–26 million, $32–35 million in 2027, and $50–55 million in 2028
- EscharEx Phase III VALUE trial progressing with enrollment and interim assessment expected by end of 2026
- Expanded NexoBrid manufacturing facility now operational, with sixfold capacity increase; regulatory approvals expected in 2026
Financial Impact
Revenue declined 15.8% YoY to $17.0 million; operating loss widened to $25.3 million from $19.4 million in 2024
Risk Factors
- Revenue heavily impacted by U.S. government budget delays; future development revenue remains uncertain
- EscharEx approval and commercial success are not guaranteed; clinical or regulatory setbacks could significantly impact valuation
- High R&D spend ($14.3M in 2025) continues to drive losses despite lower SG&A
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250013 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 7, 2026
13d ago
|
Press Release
| $17.27 $16.25 | ▼ −5.91% | ▼ −7.41% | $16.89 (−2.20%) |
|
Mar 30, 2026
7w ago
|
6-K
| $16.11 $17.27 | ▲ +7.20% | ▲ +3.26% | $16.89 (+4.84%) |
|
Mar 5, 2026
10w ago
|
Press Release
| $17.03 $16.58 | ▼ −2.64% | ▼ −1.11% | $16.89 (−0.82%) |
|
Mar 5, 2026
10w ago
|
Press Release
| $17.45 $16.58 | ▲ +4.99% | ▲ +2.75% | $16.89 (+3.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access